Psychedelinks is a weekly digest of news, business, and culture in the psychedelics industry curated by members of Emerge Law Group’s groundbreaking Psychedelics Industry Group.
Decriminalization, Legalization, & State Efforts
Oklahoma House Passes Psilocybin Decriminalization And Research Bill, Sending It To Senate
MARIJUANA MOMENT
The Oklahoma House of Representatives on Monday approved a bill to decriminalize low-level possession of psilocybin and promote research into the therapeutic potential of the psychedelic, sending it to the Senate. The legislation, sponsored by Rep. Daniel Pae (R), cleared the chamber in a 62-30 vote…
The Oklahoma House of Representatives on Monday approved a bill to decriminalize low-level possession of psilocybin and promote research into the therapeutic potential of the psychedelic, sending it to the Senate. The legislation, sponsored by Rep. Daniel Pae (R), cleared the chamber in a 62-30 vote…
Oregon Psilocybin Services Act
Measure 109 Co-Chief Petitioner Tom Eckert Resigns as Psilocybin Advisory Board Chair Amid Calls for His Departure
WILLAMETTE WEEK
Tom Eckert, the chair of Oregon’s Psilocybin Advisory Board who led the campaign to legalize hallucinogenic mushroom therapy as co-chief petitioner of Measure 109, resigned from his role on the board Thursday morning.
Tom Eckert, the chair of Oregon’s Psilocybin Advisory Board who led the campaign to legalize hallucinogenic mushroom therapy as co-chief petitioner of Measure 109, resigned from his role on the board Thursday morning.
‘It’s not medical’: Oregon wrestles with how to offer psychedelics outside the health care system
STAT NEWS
Psychedelic legalization in Oregon was widely promoted as a way to treat depression and trauma and, even among those writing regulations, there is confusion around how medical psychedelics will be.
Psychedelic legalization in Oregon was widely promoted as a way to treat depression and trauma and, even among those writing regulations, there is confusion around how medical psychedelics will be.
Research, Therapy, & Science
Johns Hopkins, Yale, and NYU are teaming up to tackle a key bottleneck that will arise as psychedelics come to market
BUSINESS INSIDER
Top academic institutions and the medical establishment are warming up to psychedelic compounds.
Top academic institutions and the medical establishment are warming up to psychedelic compounds.
Business
How Capital Markets Are Fueling Psychedelic Medicine Growth
ROLLING STONE
The psychedelic medicine industry is growing. 2011 was a seminal year for the space, with advancements in a variety of sectors. There was a wave of new psychedelic firms going public, with big name…
The psychedelic medicine industry is growing. 2011 was a seminal year for the space, with advancements in a variety of sectors. There was a wave of new psychedelic firms going public, with big name…
Psychedelics Research Is No Guarantee For Success
GREEN MARKET REPORT
When you take a big picture look at the psychedelics industry, you can easily get starry-eyed: Predictions of $6.85 billion industry by 2027. Mental health and wellness demands firing up a ready-made market. Support from more and more mainstream educational and institutional organizations creates cr…
When you take a big picture look at the psychedelics industry, you can easily get starry-eyed: Predictions of $6.85 billion industry by 2027. Mental health and wellness demands firing up a ready-made market. Support from more and more mainstream educational and institutional organizations creates cr…
Former Moderna Vice President Joins Psychedelics Company In Phase 3 Trials For Ecstasy
BENZIGA
Michael Mullette, a former Moderna vice president is taking a senior leadership position in the MAPS Public Benefit Corporation, a biotech company in the psychedelics sector. The MAPS PCB is a for-profit company wholly owned by the Multidisciplinary Association for Psychedelic Studies, a nonprofit founded in 1986 to advance patient access to psychedelic drugs for therapeutic and medical use.
Michael Mullette, a former Moderna vice president is taking a senior leadership position in the MAPS Public Benefit Corporation, a biotech company in the psychedelics sector. The MAPS PCB is a for-profit company wholly owned by the Multidisciplinary Association for Psychedelic Studies, a nonprofit founded in 1986 to advance patient access to psychedelic drugs for therapeutic and medical use.
Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research
PR NEWSWIRE
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental healthcare company advancing innovative treatments and...
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental healthcare company advancing innovative treatments and...
Upcoming Events
Microdose Psychedelic Insights to Host Psychedelic Capital: March 2022 Conference
YAHOO! FINANCE
Microdose Psychedelic Insights, the leading guide to the business of psychedelics will be hosting the upcoming Psychedelic Capital: March 2022 Conference in an entirely virtual format on Thursday March 24th, 2022 starting at 1:30pm EST. The virtu…
Microdose Psychedelic Insights, the leading guide to the business of psychedelics will be hosting the upcoming Psychedelic Capital: March 2022 Conference in an entirely virtual format on Thursday March 24th, 2022 starting at 1:30pm EST. The virtu…
Subscribe
Subscribe to Psychedelinks to receive essential weekly articles on news, business, and culture in the psychedelics industry, delivered straight to your inbox.
